The company formed pharmaceutical industry + pharmaceutical business + pharmaceutical international trade three core business segments, pharmaceutical industry focus on antiviral and cardiovascular and cerebrovascular, gynecology and pediatrics and other traditional Chinese medicine varieties.
The market share of the company's exclusive products is as high as 25%, and the company's number one customer in 2019 and 2020 will be Pfizer, and Gilead is also one of the company's important customers.The company has been actively laying out pediatric medical services since 2018, and has cooperated with children's hospitals to set up a joint venture company and carry out replication, and has already cooperated with five tertiary hospitals, such as the Pediatrics Hospital of Fudan University. The participating subsidiary cooperates with 51 selected assisted reproduction tertiary hospitals to provide one-stop professional supporting value-added services. Forecast last year's net profit growth of about 50%, the third quarter of the fund significantly increased positions, holdings close to 7%, recently announced equity incentives this year and next year to assess the net profit of 150, 250 million yuan, the current market value of only 3 billion at the beginning of the brokerage firms to give a recent target price of nearly 130% of the upside space.